• Imipenem-cilastatin, like other carbapenems, binds to bacterial penicillin binding proteins and interferes with bacterial cell wall integrity and synthesis. (nih.gov)
  • Several instances of cholestatic jaundice arising during or shortly after therapy have been reported with imipenem-cilastatin and other carbapenems. (nih.gov)
  • Imipenem and other carbapenems have not been linked to cases of acute liver failure in the published literature, but the product label for imipenem mentions that instances of jaundice and severe liver injury attributed to imipenem have been reported to the sponsor. (nih.gov)
  • The cholestatic hepatitis attributed to imipenem-cilastin and the carbapenems is probably immunoallergic and resembles the rare clinically apparent liver injury that has been linked to penicillins and cephalosporins. (nih.gov)
  • The combination of imipenem and cilastatin is available generically and under the brand name Primaxin as 250 mg or 500 mg infusion bottles for IV use or 500 mg or 750 mg vials of lyophilized powder for im injection. (nih.gov)
  • Imipenem (trade name Primaxin among others) is an intravenous β-lactam antibiotic discovered by Merck scientists Burton Christensen, William Leanza, and Kenneth Wildonger in the mid-1970s. (wikipedia.org)
  • Pharmacokinetics, safety, and tolerability of imipenem/cilastatin/relebactam in children with confirmed or suspected gram-negative bacterial infections: A Phase 1b, open-label, single-dose clinical trial. (bvsalud.org)
  • Imipenem / cilastatin /relebactam is approved for treatment of serious gram-negative bacterial infections in adults . (bvsalud.org)
  • single doses of imipenem / cilastatin /relebactam were well tolerated with no significant safety concerns identified. (bvsalud.org)
  • These results informed imipenem / cilastatin /relebactam dose selection for further pediatric clinical evaluation. (bvsalud.org)
  • The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. (merckclinicaltrials.com)
  • You should not be treated with Recarbrio if you are allergic to imipenem, cilastatin, or relebactam. (drugs.com)
  • Imipenem is always given in combination with another drug cilastatin and sometimes also relebactam. (msdmanuals.com)
  • Cilastatin and relebactam are not antibiotics. (msdmanuals.com)
  • Imipenem is in a class of medications called carbapenem antibiotics. (medlineplus.gov)
  • Imipenem is a broad spectrum carbapenem antibiotic which is used for severe bacterial infections caused by susceptible organisms. (nih.gov)
  • Imipenem is the first carbapenem antibiotic of the thienamycin class to be used clinically. (nih.gov)
  • Imipenem/cilastatin was the most common purchased antibiotic, accounting for 50.7% of total carbapenem consumption. (who.int)
  • Cilastatin is in a class of medications called dehydropeptidase inhibitors. (medlineplus.gov)
  • Because imipenem is rapidly inactivated by renal dehydropeptidase I (DHP-1), it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. (nih.gov)
  • Cilastatin is a renal dehydropeptidase inhibitor that inhibits the metabolism of imipenem by renal brush-border enzymes, thus increasing imipenem concentrations in urine. (nih.gov)
  • Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin. (nih.gov)
  • Cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the renal tubules. (medscape.com)
  • Imipenem is rapidly degraded by the renal enzyme dehydropeptidase 1 when administered alone, and is almost always coadministered with cilastatin to prevent this inactivation. (wikipedia.org)
  • Imipenem and Cilastatin for Injection, USP is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). (nih.gov)
  • Seizures and other CNS adverse reactions, such as confusional states and myoclonic activity, have been reported during treatment with imipenem and cilastatin for injection. (nih.gov)
  • If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of imipenem and cilastatin for injection re-examined to determine whether it should be decreased, or the antibacterial drug discontinued ( 5.2 ). (nih.gov)
  • Imipenem-cilastatin: Seizures were reported in patients receiving ganciclovir and imipenem-cilastatin. (nih.gov)
  • The trial gave imipenem-cilastatin to 181 patients with laboratory-confirmed ABC and then randomized them to additional treatment with either sulbactam-durlobactam or the best existing treatment, an antibiotic called colistin. (futurity.org)
  • Co-administration of imipenem and cilastatin for injection, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. (nih.gov)
  • imipenem/cilastatin will decrease the level or effect of divalproex sodium by unknown mechanism. (medscape.com)
  • Imipenem/cilastatin combination inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs). (medscape.com)
  • Imipenem and cilastatin injection is used to treat certain serious infections that are caused by bacteria, including endocarditis (infection of the heart lining and valves) and respiratory tract (including pneumonia), urinary tract, abdominal (stomach area), gynecological, blood, skin, bone, and joint infections. (medlineplus.gov)
  • Antibiotics such as imipenem and cilastatin injection will not work for colds, flu, or other viral infections. (medlineplus.gov)
  • To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). (nih.gov)
  • Imipenem-cilastatin is indicated for the treatment of severe or complicated skin, tissue, joint, respiratory tract, intraabdominal, urinary tract and urogenital infections as well as meningitis, endocarditis and sepsis due to susceptible organisms. (nih.gov)
  • For infections with multiple organisms (e.g., pelvic, intra-abdominal, or soft-tissue infections), imipenem-cilastatin may be a cost-effective and less toxic single-agent alternative to "standard" combination (e.g., aminoglycoside-penicillin plus an antianaerobic agent) therapy. (nih.gov)
  • Therapeutic effects of imipenem-cilastatin on experimental intrauterine infections in rats. (nih.gov)
  • Imipenem has a broad spectrum of activity against aerobic and anaerobic, Gram-positive and Gram-negative bacteria. (wikipedia.org)
  • Imipenem/cilastatin was approved for use in the United States in 1985. (nih.gov)
  • Imipenem was patented in 1975 and approved for medical use in 1985. (wikipedia.org)
  • The dosage of Imipenem and Cilastatin for Injection in adult patients should be based on suspected or confirmed pathogen susceptibility ( 2.1 ). (nih.gov)
  • Imipenem spectrum of bacterial susceptibility and Resistance" (PDF). (wikipedia.org)
  • There were more transient liver function test changes in the imipenem-cilastatin group, but the frequency was similar to that for beta-lactams in general. (nih.gov)
  • Imipenem-cilastatin performed well in both comparative and noncomparative trials of clinical efficacy and safety. (nih.gov)
  • Strains of methicillin-resistant staphylococci should also be considered resistant to imipenem. (nih.gov)
  • Not many species are resistant to imipenem except Pseudomonas aeruginosa (Oman) and Stenotrophomonas maltophilia. (wikipedia.org)
  • Reconstitute Imipenem and Cilastatin for Injection vial with appropriate diluent and dilute the reconstituted suspension with an appropriate infusion solution before administering by intravenous infusion ( 2.5 ). (nih.gov)
  • Imipenem-cilastatin is administered by the intravenous route only. (nih.gov)
  • Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various Gram-positive and Gram-negative bacteria. (wikipedia.org)
  • benzylpenicillin, cefazolin and, lately, imipenem/cilastatin appear to be drugs with higher neurotoxic potential than other compounds. (nih.gov)
  • Parenterally administered imipenem/cilastatin has been associated with transient, mild serum aminotransferase elevations, but it is a rare cause of clinically apparent liver disease with jaundice. (nih.gov)
  • In large clinical trials, imipenem was associated with transient and asymptomatic elevations in serum aminotransferase levels in approximately 6% of patients given the drug for 5 to 14 days. (nih.gov)
  • The cause of the mild, transient serum enzyme elevations during imipenem-cilastatin therapy is not known. (nih.gov)
  • Imipenem has the widest spectrum of antimicrobial activity of currently available beta-lactam agents and, in contrast to other beta-lactam antibiotics, lacks cross resistance with recently introduced extended-spectrum penicillins and third-generation cephalosporins. (nih.gov)
  • The adverse reaction profile of imipenem-cilastatin is similar to t that of other beta-lactam antibiotics. (nih.gov)
  • People who are allergic to penicillin and other β-lactam antibiotics should take caution if taking imipenem, as cross-reactivity rates are high. (wikipedia.org)
  • This case report bridges a void in the medical literature with regards to the psychiatric adverse effects of imipenem-cilastatin. (medscape.com)
  • A 64-year-old Hispanic man in septic shock due to urinary tract infection was initiated on imipenem-cilastatin and mechanically ventilated, following admission to hospital. (medscape.com)
  • Hashem Hospital, Jordan between August daily and group D received imipenem. (who.int)
  • Imipenem and Cilastatin for Injection, USP is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). (nih.gov)
  • Imipenem and Cilastatin for Injection, USP is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). (nih.gov)
  • 10. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. (nih.gov)
  • Bacteroides fragilis, and Enterococcus faecalis have developed resistance to imipenem to varying degrees. (wikipedia.org)
  • imipenem/cilastatin decreases effects of BCG intravesical live by pharmacodynamic antagonism. (medscape.com)
  • imipenem/cilastatin decreases effects of cholera vaccine by pharmacodynamic antagonism. (medscape.com)
  • In this phase 1, noncomparative study (ClinicalTrials.gov identifier, NCT03230916), the PK/pharmacodynamic (PD) target for imipenem was percent time of the dosing interval that unbound plasma concentration exceeded the minimum inhibitory concentration (%ƒT>MIC) of ≥30% (MIC = 2 µg/mL). (bvsalud.org)
  • More serious hepatic injury from imipenem/cilastatin is rare, but jaundice and liver test abnormalities have been reported in 0.1% of patients in prospective trials of the agent. (nih.gov)
  • Streptococcus species [ 3 ], although an in- tion as determined by the Wagner classifi- creasing number of patients have been en- cation. (who.int)
  • Imipenem and cilastatin injection is also sometimes used to treat patients who have fever and are at high risk for infection because they have a low number of white blood cells. (medlineplus.gov)
  • Patients with creatinine clearances of less than 15 mL/min should not receive Imipenem and Cilastatin for Injection unless hemodialysis is instituted within 48 hours ( 2.4 ). (nih.gov)
  • The most common side effects of imipenem are diarrhea, nausea, vomiting, skin rash, pruritus and injection site reactions. (nih.gov)